LXR Modulators for Metabolic and Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as malignant melanoma, Alzheimer's disease, Parkinson's disease, and age-related macular degeneration lack effective therapeutic agents that modulate Liver X receptor (LXR) activity to address underlying metabolic and inflammatory pathways.
Innovation Solution
Development of compounds of Formula IA, IB, or IC, and their pharmaceutical compositions that act as LXR modulators, administered to mammals to treat various conditions by modulating LXR activity, including increasing ApoE expression to suppress metastatic melanoma, reducing amyloid beta levels in Alzheimer's, and regulating inflammatory responses in Parkinson's, and improving cholesterol transport in age-related macular degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases such as malignant melanoma, Alzheimer's disease, Parkinson's disease, and age-related macular degeneration, then existing therapeutic options are maintained, but effective modulation of LXR activity to address underlying metabolic and inflammatory pathways is lacking
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (Formula IA, IB, IC) that modulate LXR activity. The compounds feature variable substituents (R1, R2, R3, R4, L1, L2, n) that can be adjusted to optimize therapeutic effectiveness for different diseases while maintaining LXR modulation capability.
2Reliability
If LXR modulating compounds are developed to enhance ApoE expression and reduce inflammatory cytokines, then therapeutic benefits for multiple diseases are achieved, but the complexity of compound structure and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the LXR modulator into distinct structural modules: a core pyrazole or pyridine ring system, variable substituents (R1-R4), and linker groups (L1, L2). This modular approach allows systematic optimization of therapeutic benefits while managing structural complexity through organized subcomponents.
Solution Approach 2:
The patent employs parameter changes by defining specific ranges and options for structural parameters (R1 as C1-C6 alkyl, R2 as C1-C6 alkyl, n as 0-2, etc.). These parameter variations enable tuning of compound properties to achieve desired therapeutic effects while maintaining synthesizability within defined chemical space.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.